invIOs to present data from clinical stage Cbl-b program at SITC 2022

invIOs announced that two abstracts on its clinical stage lead program, APN401, have been accepted for poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022) being held in Boston, MA, on November 8-12, 2022.

The posters will present new data from the ongoing Phase 1b clinical trial of APN401, a candidate treatment from invIOs’s EPiC cell therapy platform targeting the master checkpoint inhibitor Cbl-b.

Dr Romana Gugenberger, CMSO, and Dr Alexander Dohnal, Head of R&D, will attend SITC 2022 and are available for meetings during the event.

Read more